Lexicon Pharmaceuticals, Inc. (LXRX) P/E Ratio History
Historical price-to-earnings valuation from 2019 to 2021
Loading P/E history...
LXRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) trades at a price-to-earnings ratio of -12.0x, with a stock price of $1.68 and trailing twelve-month earnings per share of $-0.07.
The current P/E is 289% below its 5-year average of 6.4x. Over the past five years, LXRX's P/E has ranged from a low of 2.2x to a high of 11.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, LXRX trades at a 154% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, LXRX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LXRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LXRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 62.3 | - | -33% | |
| $2B | 6.9Lowest | 0.67Best | +817%Best | |
| $4B | 9.9 | - | +68% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
LXRX Historical P/E Data (2019–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $4.59 | $0.39 | 11.9x | +87% |
| FY2020 Q2 | $2.00 | $0.19 | 10.5x | +66% | |
| FY2020 Q1 | $1.95 | $0.62 | 3.1x | -51% | |
| FY2019 Q4 | $4.15 | $1.04 | 4.0x | -37% | |
| FY2019 Q3 | Mon Sep 30 2019 00:00:00 GM | $3.01 | $1.36 | 2.2x | -65% |
Average P/E for displayed period: 6.4x
See LXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
Is LXRX stock overvalued or undervalued?
LXRX trades at -12.0x P/E, below its 5-year average of 6.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does LXRX's valuation compare to peers?
Lexicon Pharmaceuticals, Inc. P/E of -12.0x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is LXRX's PEG ratio?
LXRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2019-2021.